Correlation of UGT1A1∗28 and ∗6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients

Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 1, 2016, Pages 90-94

  Atasilp, Chalirmporn ^a   Chansriwong, Pichai ^a   Sirachainan, Ekapob ^a   Reungwetwattana, Thanyanan ^a   Chamnanphon, Montri ^a   Puangpetch, Apichaya ^a   Wongwaisayawan, Sansanee ^a   Sukasem, Chonlaphat ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Colorectal cancer; Irinotecan; Neutropenia; UGT1A16; UGT1A1>28

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A1 28; GLUCURONOSYLTRANSFERASE 1A1 6; IRINOTECAN; UNCLASSIFIED DRUG; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACOGENETICS; PYROSEQUENCING; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; RISK; THAILAND; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; POLYMORPHISM, GENETIC; RISK; THAILAND;

EID: 84957991755     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2015.12.004     Document Type: Article

References (27)

1. M. Ramesh, P. Ahlawat, and N.R. Srinivas Irinotecan and its active metabolite, SN-38: Review of bioanalytical methods and recent update from clinical pharmacology perspectives BMC 24 2010 104 123
2. -28 polymorphisms: A potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer Pharmacogenomics 15 2014 1171 1174
3. K. Hirose, C. Kozu, K. Yamashita, E. Maruo, M. Kitamura, J. Hasegawa, and et al. Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene Oncol Lett 3 2012 694 698
4. J. Gao, J. Zhou, Y. Li, M. Lu, R. Jia, and L. Shen UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients Med Oncol 30 2013 604
5. K. Araki, K. Fujita, Y. Ando, F. Nagashima, W. Yamamoto, H. Endo, and et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 2006 1255 1259
6. -28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma Cancer 112 2008 1932 1940
7. L. Iyer, C.D. King, P.F. Whitington, M.D. Green, S.K. Roy, T.R. Tephly, and et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 1998 847 854
8. E. Martinez-Balibrea, A. Abad, A. Martinez-Cardus, A. Gines, M. Valladares, M. Navarro, and et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Br J Cancer 103 2010 581 589
9. K. Inoue, M. Sonobe, Y. Kawamura, T. Etoh, M. Takagi, T. Matsumura, and et al. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy Tohoku J Exp Med 229 2013 107 114
10. E. Beutler, T. Gelbart, and A. Demina Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95 1998 8170 8174
11. -28 genotype testing in colorectal cancer patients Cancer 117 2011 3156 3162
12. J.F. Cote, S. Kirzin, A. Kramar, J.F. Mosnier, M.D. Diebold, I. Soubeyran, and et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan Clin Cancer Res 13 2007 3269 3275
13. Campostar (irinotecan HCl), hepatic dysfunction, pancreatitis, UGT1A1, July 21, 2005, final label [Internet]. July [cited July 26, 2015]. Available from: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/020571s026lbl.pdf.
14. -6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer Cancer Chemother Pharmacol 68 2011 279 284
15. M.A. Boyd, P. Srasuebkul, K. Ruxrungtham, P.I. Mackenzie, V. Uchaipichat, M. Stek Jr., and et al. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir Pharmacogenet Genomics 16 2006 321 329
16. C. Sukasem, C. Atasilp, P. Chansriwong, M. Chamnanphon, A. Puangpetch, and E. Sirachainan Development of pyrosequencing method for detection of UGT1A1 polymorphisms in Thai colorectal cancers J Clin Lab Anal 29 2014 1 6
17. -28 in three major ethnic groups from Malaysia Indian J Med Res 136 2012 249 259
18. A. Premawardhena, C.A. Fisher, Y.T. Liu, I.C. Verma, S. de Silva, M. Arambepola, and et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): Hematologic and evolutionary implications Blood Cells Mol Dis 31 2003 98 101
19. -28 Pharmacogenet Genomics 17 2007 497 504
20. Y. Ando, H. Saka, M. Ando, T. Sawa, K. Muro, H. Ueoka, and et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis Cancer Res 60 2000 6921 6926
21. E. Marcuello, A. Altes, A. Menoyo, E. Del Rio, M. Gomez-Pardo, and M. Baiget UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 2004 678 682
22. M. Tziotou, V. Kalotychou, A. Ntokou, R. Tzanetea, I. Armenis, M. Varsou, and et al. Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: Low dose does not protect from toxicity Ecancermedicalscience 8 2014 428
23. F. Innocenti, S.D. Undevia, L. Iyer, P.X. Chen, S. Das, M. Kocherginsky, and et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 2004 1382 1388
24. E. Rouits, M. Boisdron-Celle, A. Dumont, O. Guerin, A. Morel, and E. Gamelin Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients Clin Cancer Res 10 2004 5151 5159
25. -28 genotype and irinotecan-induced neutropenia: Low doses also increase risk Clin Cancer Res 16 2010 3832 3842
26. -28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients Cancer Sci 98 2007 1461 1467
27. -28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients Cancer Chemother Pharmacol 73 2014 779 788